On Tuesday, Theravance Biopharma Inc (NASDAQ: TBPH) was 22.68% up from the session before settling in for the closing price of $15.08. A 52-week range for TBPH has been $7.90 – $15.34.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 22.95%. When this article was written, the company’s average yearly earnings per share was at 256.38%. With a float of $46.82 million, this company’s outstanding shares have now reached $50.36 million.
Theravance Biopharma Inc (TBPH) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Theravance Biopharma Inc stocks. The insider ownership of Theravance Biopharma Inc is 7.21%, while institutional ownership is 94.55%. The most recent insider transaction that took place on Jul 14 ’25, was worth 113,870. In this transaction SVP, COMM & MEDICAL AFFAIRS of this company sold 10,000 shares at a rate of $11.39, taking the stock ownership to the 326,918 shares. Before that another transaction happened on Jul 14 ’25, when Company’s Officer proposed sale 10,000 for $11.39, making the entire transaction worth $113,869.
Theravance Biopharma Inc (TBPH) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.05 earnings per share (EPS) during the time that was better than consensus figure (set at -0.08) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 256.38% per share during the next fiscal year.
Theravance Biopharma Inc (NASDAQ: TBPH) Trading Performance Indicators
You can see what Theravance Biopharma Inc (TBPH) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.07. Likewise, its price to free cash flow for the trailing twelve months is 3.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.23, a number that is poised to hit 0.85 in the next quarter and is forecasted to reach 0.88 in one year’s time.
Technical Analysis of Theravance Biopharma Inc (TBPH)
Compared to the last year’s volume of 0.31 million, its volume of 0.57 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 76.61%.
During the past 100 days, Theravance Biopharma Inc’s (TBPH) raw stochastic average was set at 94.60%, which indicates a significant increase from 91.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.71 in the past 14 days, which was higher than the 0.45 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.32, while its 200-day Moving Average is $11.30. Nevertheless, the first resistance level for the watch stands at $19.78 in the near term. At $21.07, the stock is likely to face the second major resistance level. The third major resistance level sits at $23.17. If the price goes on to break the first support level at $16.39, it is likely to go to the next support level at $14.29. Should the price break the second support level, the third support level stands at $13.00.
Theravance Biopharma Inc (NASDAQ: TBPH) Key Stats
There are 50,361K outstanding shares of the company, which has a market capitalization of 931.69 million. As of now, sales total 64,380 K while income totals -56,420 K. Its latest quarter income was 26,200 K while its last quarter net income were 54,840 K.
